Product Code: DMKC0138547
Faced with tough competitive conditions and declining growth rates, many pharma companies are looking towards emerging markets as sources of revenue growth. Growing economies and a burgeoning middle class, as well as expanding healthcare systems, have resulted in high growth rates and increased demand for Western medicines.
However, as developing countries strive to improve access to healthcare by expanding insurance coverage and investing in healthcare system infrastructure, growing patient expectations are increasingly forcing them to find a way of reconciling demand with limited resources. Consequently, governments and policymakers have begun to utilize health technology assessment to this end, and this new trend has changed the market access landscape and the way in which pharma interacts with key stakeholders.
This report addresses the following questions:
- How is HTA use impacting access in emerging markets?
- What are the differences between HTA use in different emerging market countries?
- How have pharma's strategies adapted in reaction to the changes brought about by HTA?
- What channels exist for pharma-HTA engagement?
- What are the key lessons for success in overcoming hurdles presented by HTA in emerging markets?
TABLE OF CONTENTS
DRIVERS AND RESISTORS OF HTA USE
- 1. Healthcare growth containment drives need for HTA
- 2. A number of obstacles remain to effective HTA use
- 3. More challenging market access conditions are resulting from HTA use
- 4. Bibliography
HTA IS IMPLEMENTED IN A VARIETY OF WAYS
- 5. HTA is adopted and implemented in a variety of ways depending on a country's needs and Preferences
- 6. International collaboration is shaping HTA development and capacity building in emerging markets, but variations will remain
- 7. Bibliography
- PHARMA'S INVESTMENT IN HEOR IS GROWING
- 8. Growing pharma sales in the public segment necessitate shift in strategy
- 9. Pharma's investment in HEOR in emerging markets is growing, but a pragmatic approach is critical to maximize ROI
- 10. Bibliography
HTA AND STAKEHOLDER ENGAGEMENT
- 11. Formal HTA advice channels focus on technical aspects
- 12. Informal engagement of stakeholders and policy makers is commonplace
- 13. Public-private partnerships present an opportunity for wider engagement with governments and providers
- 14. Bibliography
- 15. Brazil has established itself as a leader in HTA in Latin America
- 16. Universal healthcare coverage necessitated introduction of a formal HTA process
- 17. Establishment of CONITEC represents a major step in strengthening HTA process in Brazil
- 18. Communication with CONITEC focuses on the technical checking of the dossiers, but the agency is open to further engagement
- 19. Threat of spill-over effect into private insurance coverage enhances importance of CONITEC approval
- 20. Bibliography
- 21. China lags behind in its capacity to use HTA, but slow change is set to occur
- 22. Universal health insurance coverage as a result of healthcare reforms
- 23. Bibliography
- 24. HTA in Mexico lags behind Brazil
- 25. The Mexican health insurance system is fragmented
- 26. The CSG is the key HTA body in Mexico and decides on national reimbursement
- 27. Bibliography
- 28. Poland is a leader in HTA in Central and Eastern Europe
- 29. Public health insurance provides coverage to 98% of the Polish people
- 30. Bibliography
- 31. South Korea's HIRA has emerged as the leader in HTA in the Asia Pacific region
- 32. South Korea's health insurance system is based on a single major payer
- 33. HIRA and NECA are the key HTA bodies in South Korea
- 34. Bibliography
- 35. Taiwan has introduced HTA, but has limited capacity to carry out full assessment
- 36. The Taiwanese healthcare system has a single payer
- 37. The pricing and reimbursement process was reformed in 2013
- 38. Bibliography